2 completed, 2 recruiting, 1 unknown. 2 Not applicable, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow Schwannomatosis: new trials by email Literature Review of Schwannomatosis trials Research Report on Schwannomatosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Screening Trial for Pain Relief in Schwannomatosis (STARFISH) Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo - Schwannomatosis, Schwannomas | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2023-08-31 | 2026-07-24 |
| Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis Tanezumab, Placebo - Schwannomatosis, Pain | Phase 2 | Unknown | Massachusetts General Hospital | 9 | 2020-04-30 | 2024-03-13 |
| Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing Stress and Symptom Management Program 1, Stress and Symptom Management Program 2 - Neurofibromatoses, Neurofibromatosis 1 | Not applicable | Completed | Massachusetts General Hospital | 228 | 2017-10-01 | 2025-12-24 |
| Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype The Relaxation Response Resiliency Program (3RP) via Skype - Neurofibromatosis, Neurofibromatosis I | Not applicable | Completed | Massachusetts General Hospital | 65 | 2014-03-01 | 2016-06-23 |
| The NF Registry Sponsored by the Children's Tumor Foundation Neurofibromatosis 1, Neurofibromatosis 2 | Recruiting | The Children's Tumor Foundation | 20000 | 2012-06-01 | 2026-10-22 |
Neurofibromatoses (3) · Neurofibromatosis 1 (3) · Neurofibromatosis 2 (3) · Neurilemmoma (2) · Pain (2) · Behavior (1) · Chronic Pain (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Nerve Sheath Neoplasms (5) · Neuroectodermal Tumors (5) · Neuroendocrine Tumors (5) · Neuroma (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Heredodegenerative Disorders, Nervous System (4) · Nervous System Diseases (4) · Neurodegenerative Diseases (4) · Neuromuscular Diseases (4) · Peripheral Nervous System Diseases (4)
Saline Solution (1) · erenumab (1) · siltuximab (1) · tanezumab (1)
Massachusetts General Hospital (4) · The Children's Tumor Foundation (1)
United States (5)
Ana-Maria Vranceanu, PhD (2) · Kate Kelts, B.S.N. (1) · Scott Plotkin, MD (1) · Scott R Plotkin (1)
PMID 30355560, PMID 32421171, PMID 34409538, PMID 34570301, PMID 35064449, PMID 35925531, PMID 36038003, PMID 36651958, PMID 36798353, PMID 37378983, PMID 37440099, PMID 38318960, PMID 39917761, PMID 40773151